KEYNOTE-024

NCT02142738 📎

Regimen

Experimental
pembrolizumab
Control
platinum doublet

Population

PD-L1≥50% advanced NSCLC, chemo-naive

Key finding

mPFS 10.3 vs 6.0 mo, HR 0.50 (0.37-0.68); mOS 30.0 vs 14.2 mo

Source: PMID 27718847

Timeline

  • Enrollment start: 2014-08-25 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.174)
  • CSCO NSCLC 2025 ⚠️ OCR source